Fortress Biotech Inc.

0.3114-0.0017-0.54%Vol 118.07K1Y Perf -63.32%
Oct 3rd, 2023 16:00 DELAYED
BID0.3037 ASK0.3200
Open0.3131 Previous Close0.3131
Pre-Market- After-Market0.31
 - -  0.00 -0.45%
Target Price
8.50 
Analyst Rating
Strong Buy 1.00
Potential %
2.63K 
Finscreener Ranking
★★★★+     56.30
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★+     44.69
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★+     49.29
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
3.50 
Earnings Rating
Sell
Market Cap41.35M 
Earnings Date
13th Nov 2023
Alpha-0.02 Standard Deviation0.28
Beta2.09 

Today's Price Range

0.30300.3181

52W Range

0.28061.16

5 Year PE Ratio Range

-3.70-1.40

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
10.52%
1 Month
-21.47%
3 Months
-44.80%
6 Months
-61.35%
1 Year
-63.32%
3 Years
-92.07%
5 Years
-78.99%
10 Years
-96.23%

TickerPriceChg.Chg.%
FBIO0.3114-0.0017-0.54
AAPL172.40-1.3500-0.78
GOOG133.30-1.8700-1.38
MSFT313.39-8.4100-2.61
XOM115.830.20000.17
WFC38.67-0.9400-2.37
JNJ155.340.19000.12
FB196.640.99000.51
GE107.76-1.0300-0.95
JPM142.71-1.0600-0.74
Financial StrengthValueIndustryS&P 500US Markets
2.20
2.40
0.65
2.03
-19.40
Leverage Ratio 4.60
ProfitabilityValueIndustryS&P 500US Markets
56.60
-275.10
-264.20
-282.90
-
RevenueValueIndustryS&P 500US Markets
59.34M
0.55
22.07
-6.86
Earnings HistoryEstimateReportedSurprise %
Q02 2023-0.26-0.247.69
Q01 2023-0.19-0.21-10.53
Q04 2022-0.22-0.30-36.36
Q03 2022-0.27-0.257.41
Q02 2022-0.20-0.24-20.00
Q01 2022-0.28-0.1835.71
Q04 20210.10-0.38-480.00
Q03 2021-0.08-0.26-225.00
Earnings Per EndEstimateRevision %Trend
9/2023 QR-0.26-13.04Negative
12/2023 QR-0.30-30.43Negative
12/2023 FY-0.932.11Positive
12/2024 FY-0.2860.00Positive
Next Report Date13th Nov 2023
Estimated EPS Next Report-0.26
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume118.07K
Shares Outstanding132.79K
Shares Float96.14M
Trades Count322
Dollar Volume36.76K
Avg. Volume402.18K
Avg. Weekly Volume330.75K
Avg. Monthly Volume296.73K
Avg. Quarterly Volume579.06K

Fortress Biotech Inc. (NASDAQ: FBIO) stock closed at 0.3131 per share at the end of the most recent trading day (a 7.85% change compared to the prior day closing price) with a volume of 382.02K shares and market capitalization of 41.35M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 93 people. Fortress Biotech Inc. CEO is Lindsay A. Rosenwald.

The one-year performance of Fortress Biotech Inc. stock is -63.32%, while year-to-date (YTD) performance is -52.2%. FBIO stock has a five-year performance of -78.99%. Its 52-week range is between 0.2806 and 1.16, which gives FBIO stock a 52-week price range ratio of 3.50%

Fortress Biotech Inc. currently has a PE ratio of -0.80, a price-to-book (PB) ratio of 1.39, a price-to-sale (PS) ratio of 1.46, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -27.26%, a ROC of -44.48% and a ROE of -130.13%. The company’s profit margin is -%, its EBITDA margin is -264.20%, and its revenue ttm is $59.34 Million , which makes it $0.55 revenue per share.

Of the last four earnings reports from Fortress Biotech Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.26 for the next earnings report. Fortress Biotech Inc.’s next earnings report date is 13th Nov 2023.

The consensus rating of Wall Street analysts for Fortress Biotech Inc. is Strong Buy (1), with a target price of $8.5, which is +2 629.61% compared to the current price. The earnings rating for Fortress Biotech Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Fortress Biotech Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Fortress Biotech Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 13.92, ATR14 : 0.04, CCI20 : -82.07, Chaikin Money Flow : -0.51, MACD : -0.04, Money Flow Index : 37.65, ROC : -15.38, RSI : 38.89, STOCH (14,3) : 25.12, STOCH RSI : 1.00, UO : 26.24, Williams %R : -74.88), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Fortress Biotech Inc. in the last 12-months were: David Jin (Buy at a value of $32 800), Eric K. Rowinsky (Buy at a value of $10 000), J. Jay Lobell (Buy at a value of $250 000), Lindsay A. Rosenwald (Buy at a value of $4 152 234), Lobell J. (Buy at a value of $251 497), Lucy Lu (Buy at a value of $20 060), Michael S. Weiss (Buy at a value of $999 999)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
7 (100.00 %)
7 (100.00 %)
7 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Fortress Biotech Inc.

Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Targadox, Exelderm, Ceracade, Luxamend, and Dermasorb. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology, therapeutics sectors.

CEO: Lindsay A. Rosenwald

Telephone: +1 781 652-4500

Address: 2 Gansevoort Street, New York 10014, NY, US

Number of employees: 93

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

56%44%

Bearish Bullish

59%41%

 

News

Stocktwits